Methylated Glutathione S-transferase 1 (mGSTP1) is a Potential Plasma Free DNA Epigenetic Marker of Prognosis and Response to Chemotherapy in Castrate-resistant Prostate Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2014 Aug 22

PMID 25144624

Citations 35

Authors

K L Mahon

W Qu

J Devaney

C Paul

L Castillo

R J Wykes

M D Chatfield

M J Boyer

M R Stockler

G Marx

H Gurney

G Mallesara

P L Molloy

L G Horvath

S J Clark

Affiliations

Soon will be listed here.

Abstract

Background: Glutathione S-transferase 1 (GSTP1) inactivation is associated with CpG island promoter hypermethylation in the majority of prostate cancers (PCs). This study assessed whether the level of circulating methylated GSTP1 (mGSTP1) in plasma DNA is associated with chemotherapy response and overall survival (OS).

Methods: Plasma samples were collected prospectively from a Phase I exploratory cohort of 75 men with castrate-resistant PC (CRPC) and a Phase II independent validation cohort (n=51). mGSTP1 levels in free DNA were measured using a sensitive methylation-specific PCR assay.

Results: The Phase I cohort identified that detectable baseline mGSTP1 DNA was associated with poorer OS (HR, 4.2 95% CI 2.1-8.2; P<0.0001). A decrease in mGSTP1 DNA levels after cycle 1 was associated with a PSA response (P=0.008). In the Phase II cohort, baseline mGSTP1 DNA was a stronger predictor of OS than PSA change after 3 months (P=0.02). Undetectable plasma mGSTP1 after one cycle of chemotherapy was associated with PSA response (P=0.007).

Conclusions: We identified plasma mGSTP1 DNA as a potential prognostic marker in men with CRPC as well as a potential surrogate therapeutic efficacy marker for chemotherapy and corroborated these findings in an independent Phase II cohort. Prospective Phase III assessment of mGSTP1 levels in plasma DNA is now warranted.

Citing Articles

Investigating the prognostic utility of promoter methylation in prostate cancer.

Pidsley R, Lam D, Qu W, Stricker P, Kench J, Horvath L BJUI Compass. 2025; 5(12):1299-1306.

PMID: 39744075 PMC: 11685177. DOI: 10.1002/bco2.445.

Extracellular vesicles as a promising biomarker resource in liquid biopsy for cancer.

Tamura T, Yoshioka Y, Sakamoto S, Ichikawa T, Ochiya T Extracell Vesicles Circ Nucl Acids. 2024; 2(2):148-174.

PMID: 39703905 PMC: 11656527. DOI: 10.20517/evcna.2021.06.

Role of DNA methylation transferase in urinary system diseases: From basic to clinical perspectives (Review).

Yang Y, Wang Y, Fan X, Xu X, Wang H, Wang X Int J Mol Med. 2024; 55(2).

PMID: 39575487 PMC: 11611324. DOI: 10.3892/ijmm.2024.5460.

Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review.

Maekawa S, Takata R, Obara W Cancers (Basel). 2024; 16(3).

PMID: 38339274 PMC: 10854717. DOI: 10.3390/cancers16030523.

Epigenetic (De)regulation in Prostate Cancer.

Xu C, Zhao S, Cai L Cancer Treat Res. 2023; 190:321-360.

PMID: 38113006 PMC: 11421856. DOI: 10.1007/978-3-031-45654-1_10.

References

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

Jeronimo C, Usadel H, Henrique R, Silva C, Oliveira J, Lopes C . Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology. 2002; 60(6):1131-5. DOI: 10.1016/s0090-4295(02)01949-0. View

Ruzza P, Rosato A, Rossi C, Floreani M, Quintieri L . Glutathione transferases as targets for cancer therapy. Anticancer Agents Med Chem. 2009; 9(7):763-77. DOI: 10.2174/187152009789056895. View

Reibenwein J, Pils D, Horak P, Tomicek B, Goldner G, Worel N . Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance. Prostate. 2006; 67(4):427-32. DOI: 10.1002/pros.20533. View

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

Scher H, Jia X, de Bono J, Fleisher M, Pienta K, Raghavan D . Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009; 10(3):233-9. PMC: 2774131. DOI: 10.1016/S1470-2045(08)70340-1. View

Bryzgunova O, Morozkin E, Yarmoschuk S, Vlassov V, Laktionov P . Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients. Ann N Y Acad Sci. 2008; 1137:222-5. DOI: 10.1196/annals.1448.039. View

Rand K, Qu W, Ho T, Clark S, Molloy P . Conversion-specific detection of DNA methylation using real-time polymerase chain reaction (ConLight-MSP) to avoid false positives. Methods. 2002; 27(2):114-20. DOI: 10.1016/s1046-2023(02)00062-2. View

Millar D, Ow K, Paul C, Russell P, Molloy P, Clark S . Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer. Oncogene. 1999; 18(6):1313-24. DOI: 10.1038/sj.onc.1202415. View

10.

Petrylak D, Tangen C, Hussain M, Lara Jr P, Jones J, Taplin M . Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351(15):1513-20. DOI: 10.1056/NEJMoa041318. View

11.

Okegawa T, Nutahara K, Higashihara E . Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer. Int J Urol. 2010; 17(5):466-75. DOI: 10.1111/j.1442-2042.2010.02502.x. View

12.

Danila D, Heller G, Gignac G, Gonzalez-Espinoza R, Anand A, Tanaka E . Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007; 13(23):7053-8. DOI: 10.1158/1078-0432.CCR-07-1506. View

13.

Roupret M, Hupertan V, Yates D, Catto J, Rehman I, Meuth M . Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res. 2007; 13(6):1720-5. DOI: 10.1158/1078-0432.CCR-06-2467. View

14.

Bastian P, Palapattu G, Lin X, Yegnasubramanian S, Mangold L, Trock B . Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res. 2005; 11(11):4037-43. DOI: 10.1158/1078-0432.CCR-04-2446. View

15.

Tannock I, de Wit R, Berry W, Horti J, Pluzanska A, Chi K . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351(15):1502-12. DOI: 10.1056/NEJMoa040720. View

16.

Jeronimo C, Bastian P, Bjartell A, Carbone G, Catto J, Clark S . Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol. 2011; 60(4):753-66. DOI: 10.1016/j.eururo.2011.06.035. View

17.

Cairns P, Esteller M, Herman J, Schoenberg M, Jeronimo C, Sanchez-Cespedes M . Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res. 2001; 7(9):2727-30. View

18.

Armstrong A, Garrett-Mayer E, Yang Y, Carducci M, Tannock I, de Wit R . Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007; 25(25):3965-70. DOI: 10.1200/JCO.2007.11.4769. View

19.

Rushmore T, Pickett C . Glutathione S-transferases, structure, regulation, and therapeutic implications. J Biol Chem. 1993; 268(16):11475-8. View

20.

Danila D, Fleisher M, Scher H . Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res. 2011; 17(12):3903-12. PMC: 3743247. DOI: 10.1158/1078-0432.CCR-10-2650. View